12:00 AM
 | 
Jan 04, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

5G1: Phase IIb

ALXN published in Circulation previously reported results of Phase I/II and IIa trials of 5G1.1-SC. The product reduced cardiac damage and the incidence of brain deficits compared...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >